N-(4-nitrophenyl)pyrrolidine-1-carboxamide | 35799-21-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-nitrophenyl)pyrrolidine-1-carboxamide
• CAS: 35799-21-4
• 化学式: C₁₁H₁₃N₃O₃
• mdl: MFCD01615307
• 分子量: 235.243
• InChiKey: VUSDWGHGQISTQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  78.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-nitrophenyl)pyrrolidine-1-carboxamide 在 铁粉 、 氯化铵 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 20.0h， 生成 pyrrolidine-1-carboxylic acid (4-acryloylaminophenyl)-amide
  参考文献：
  名称：

  Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease

  摘要：

  Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.

  DOI：

  10.1021/jm201310y
• 作为产物：
  描述：

  3-pyrrolidino-2-benzopyran-1-one 、 4-nitrophenyl azide 以8%的产率得到
  参考文献：
  名称：

  BOYD G. V.; MONTEIL R. L., J. CHEM. SOC. PERKIN TRANS. PART 1, 1980, NO 4, 846-848

  摘要：

  DOI：

文献信息

• [DE] THIOZOLIDINONE, DEREN HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS<br/>[FR] THIAZOLIDINONES, LEUR PRODUCTION ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：SCHERING AG

  公开号：WO2005042505A1

  公开（公告）日：2005-05-12

  Es werden Thiazolidinone der allgemeinen Formel ( I ), in der Q, A, B, X, R1 und R2 die in der Beschreibung angegebenen Bedeutungen haben, sowie der allgemeinen Formel (IA) in der Q, A, B, X, R1 und R2a die in der Beschreibung angegebenen Bedeutungen haben, deren Herstellung und Verwendung als Inhibitoren der Polo Like Kinase (PLK) zur Behandlung verschiedener Erkrankungen sowie Zwischenprodukte zur Herstellung der Thiazolidinone beschrieben.

  通用公式（I）中的噻唑烷酮，其中Q、A、B、X、R1和R2具有描述中指定的含义，以及通用公式（IA）中的Q、A、B、X、R1和R2a具有描述中指定的含义，它们的制备和用途作为Polo-Like激酶（PLK）的抑制剂，用于治疗各种疾病，以及用于制备噻唑烷酮的中间体已经描述。
• Synthesis of ureas in the bio-alternative solvent Cyrene
  作者：Liam Mistry、Kopano Mapesa、Thomas W. Bousfield、Jason E. Camp

  DOI：10.1039/c7gc00908a

  日期：——

  Cyrene as a bio-alternative solvent: a highly efficient, waste minimizing protocol for the synthesis of ureas from isocyanates and secondary amines in the bio-available solvent Cyrene is reported. This method eliminated the use of toxic solvents, such as DMF, and established a simple work-up procedure for removal of the Cyrene, which led to a 28-fold increase in molar efficiency versus industrial standard

  乙炔作为生物替代溶剂：报道了一种在生物可用溶剂丙炔中由异氰酸酯和仲胺合成尿素的高效，废物最小化方案。该方法消除了使用有毒溶剂（例如DMF）的麻烦，并建立了一种简单的后苯脱除后处理程序，与工业标准流程相比，摩尔效率提高了28倍。
• Thiazolidinones, their production and use as pharmaceutical agents
  申请人：Siemeister Gerhard

  公开号：US20070037862A1

  公开（公告）日：2007-02-15

  Thiazolidinones of general formula I in which Q, A, B, X, R 1 and R 2 have the meanings that are indicated in the description, as well as those of general formula IA in which Q, A, B, X, R 1 and R 2a have the meanings that are indicated in the description, their production and use as inhibitors of the polo-like kinase (PLK) for treating various diseases as well as intermediate products for the production of thiazolidinones are described.

  通用公式I中的噻唑烷酮，其中Q、A、B、X、R1和R2具有描述中指示的含义，以及通用公式IA中的噻唑烷酮，其中Q、A、B、X、R1和R2ahave具有描述中指示的含义，描述了它们作为极化样激酶（PLK）抑制剂用于治疗各种疾病以及用于噻唑烷酮的生产和使用的中间体产品。
• Boyd, Gerhard V.; Monteil, Rene L., Journal of the Chemical Society. Perkin transactions I, 1980, p. 846 - 848
  作者：Boyd, Gerhard V.、Monteil, Rene L.

  DOI：——

  日期：——
• Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease
  作者：Michael E. Prime、Ole A. Andersen、John J. Barker、Mark A. Brooks、Robert K. Y. Cheng、Ian Toogood-Johnson、Stephen M. Courtney、Frederick A. Brookfield、Christopher J. Yarnold、Richard W. Marston、Peter D. Johnson、Siw F. Johnsen、Jordan J. Palfrey、Darshan Vaidya、Sayeh Erfan、Osamu Ichihara、Brunella Felicetti、Shilpa Palan、Anna Pedret-Dunn、Sabine Schaertl、Ina Sternberger、Andreas Ebneth、Andreas Scheel、Dirk Winkler、Leticia Toledo-Sherman、Maria Beconi、Douglas Macdonald、Ignacio Muñoz-Sanjuan、Celia Dominguez、John Wityak

  DOI：10.1021/jm201310y

  日期：2012.2.9

  Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.